Evidence map›Paper›PMID 28353184›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2017

High pneumococcal DNA load, procalcitonin and suPAR levels correlate to severe disease development in patients with pneumococcal pneumonia.

A J M Loonen, C Kesarsing, R Kusters, M Hilbink, P C Wever, A J C van den Brule

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04652167 (What is the Diagnostic and Prognostic Accuracy of C-reactive Protein, Serum Procalcitonin and Soluble Urokinase Plasminogen Activator Receptor in the Initial Investigation of Patients With Suspected Community-acquired Pneumonia), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04652167 completednot on this mapstarted 2021, after this paper: background citation

What is the Diagnostic and Prognostic Accuracy of C-reactive Protein, Serum Procalcitonin and Soluble Urokinase Plasminogen Activator Receptor in the Initial Investigation of Patients With Suspected Community-acquired Pneumonia

TypeobservationalSponsorUniversity of Southern DenmarkRan2021 to 2022Enrolled411ConditionsPneumonia, BacterialArmsPCT, suPAR, Standard care
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Estimating bacterial load in S. aureus and E. coli bacteremia using bacterial growth graph from the continuous monitoring blood culture system.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  5. Diabetes Mellitus and Pneumococcal Pneumonia.Diagnostics (Basel, Switzerland) · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

A J M LoonenLaboratory of Molecular Diagnostics, Jeroen Bosch Hospital, P.O Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.
C KesarsingLaboratory of Molecular Diagnostics, Jeroen Bosch Hospital, P.O Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.
R KustersDepartment of Clinical Chemistry and Haematology, Jeroen Bosch Hospital, P.O Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.
M HilbinkJeroen Bosch Academy, P.O Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.
P C WeverDepartment of Medical Microbiology and Infection Control, Jeroen Bosch Hospital, P.O Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.
A J C van den BruleLaboratory of Molecular Diagnostics, Jeroen Bosch Hospital, P.O Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands. a.v.d.brule@jbz.nl.
Jeroen Bosch Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Community-acquired pneumonia (CAP) is mostly caused by Streptococcus pneumoniae. Identification of the pathogen causing CAP can be achieved by conventional culture techniques of sputum and/or blood, antigen detection from urine or molecular analysis. However, it remains difficult to determine patients who are at risk of severe disease development (intensive care unit [ICU] admittance and/or death). In this retrospective study, 121 patients admitted to the emergency department with pneumonia symptoms were included. Several markers of infection (pneumococcal DNA load in blood (real-time LytA PCR), white blood cell (WBC) count, C-reactive protein (CRP), procalcitonin (PCT) and soluble urokinase plasminogen activator receptor (suPAR) levels) were assessed for their ability to predict severe disease development. Of 121 patients, 6 were excluded from the study because of an alternative diagnosis, whereas 8 were excluded from biomarker analysis because of the presence of co-morbidities. Of the 115 patients analysed by the LytA PCR, 23 were positive. PCR detected S. pneumoniae DNA in 82% of patients with positive blood culture for S. pneumoniae. PCR missed three samples from patients in which S. pneumoniae was recovered by blood cultures. However, eight additional LytA PCR-positive samples were detected from patients whose blood cultures remained negative. Pneumococcal DNA load was also monitored in time for 31 patients, of whom 11 had positive PCR results. For 10 out of 11 (91%) positive PCR patients, a clear increase in Ct-values was observed, indicating a lower pneumococcal DNA load in the blood as a result of antibiotic therapy. Biomarker analysis was performed in 107 patients, of whom 29 showed severe disease development. Pneumococcal DNA load (p = 0.026), PCT (p = 0.046) and suPAR (p = 0.001) levels most reliably predicted severe disease development. In conclusion, in patients with CAP, higher pneumococcal DNA load, PCT and suPAR values are associated with severe disease development (ICU admission and/or death). These biomarkers may be useful tools for triage of patients suspected of having CAP in the emergency department.

Indexed as

DNA, BacterialBiomarkersBlood Cell CountCalcitoninFemaleHumansMalePneumonia, PneumococcalReceptors, Urokinase Plasminogen ActivatorRetrospective StudiesROC CurveSeverity of Illness IndexStreptococcus pneumoniaeBiomarkersCalcitoninDNA, BacterialReceptors, Urokinase Plasminogen ActivatorBlood CultureBlood Culture ResultNegative Blood CultureReceiver Operating CharacteristicWhite Blood Cell Count

Identifiers

PMID28353184
OpenAlexW2598963014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.